Loading
Orlucent
Orlucent is a California company making a handheld imaging system that uses a fluorescent agent on the skin to judge whether a mole is turning into melanoma. It is in clinical trials and not yet approved for diagnosis in the United States.
Also called: Orlucent, Inc.ORLUCENT, INC.
Overview
Orlucent, Inc., of Los Gatos, California, has developed a handheld fluorescent molecular imaging system, the Orlucent System, to assess the likelihood of a mole's transition to melanoma; the website states that it is in clinical trials and for research use only in the United States. In fiscal year 2026 NCI awarded it USD 1,556,529 under SBIR Direct-to-Phase II grant 1R44CA306680-01A1 to develop manufacturing controls for ORL1, the fluorescent imaging agent used by its skin fluorescent imaging system; the award abstract reports 100 per cent sensitivity and 95.7 per cent specificity in distinguishing melanomas from non-melanomas in preliminary studies.
Headquarters
Los Gatos, CA, US
Scorecard
All companies#792of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase II (R44) award 1R44CA306680-01A1: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas | 2026 | $2M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Products
1Handheld fluorescent molecular skin imaging system with topical imaging agent (device)
The Orlucent System is a handheld skin imager from Orlucent that uses a fluorescent agent to judge whether a mole may be becoming melanoma. It is in clinical trials and for research use only in the United States.
Notes
- The sensitivity and specificity figures are from preliminary studies reported in the company's award abstract, not a published trial. Founding year not stated. Read on orlucent.com and NIH RePORTER on 4 November 2026.
Connected
6Similar pages
cancers
fronts
technologies
Devices and software
Handheld fluorescent molecular skin imaging system with topical imaging agent (device)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
orlucent.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/